Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market: By Product Type (Vaccines, and Monoclonal Antibodies), By Target Population (Infants, Older Adults, and Pregnant Women), By Clinical Trial Phase (Phase I, Phase II, and Phase III) and Geography

Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market is poised to grow at a CAGR of 27.1% from 2024 to 2030. RSV is a major cause of lower respiratory tract infections, particularly severe in infants, older adults, and immunocompromised individuals. Globally, RSV causes an estimated 33 million cases of acute lower respiratory infection in children under 5 years annually, resulting in more than 3 million hospitalizations and about 60,000 in-hospital deaths in children under 5 years. The increasing recognition of RSV's significant health and economic burden drives the market for vaccines and antibodies. Additionally, the COVID-19 pandemic has heightened awareness about respiratory viruses, accelerating research and development in this field.

Technological advancements, including the application of mRNA technology and structure-based vaccine design, contribute to market growth by improving vaccine efficacy and production efficiency. Recent breakthroughs in understanding RSV's molecular structure and immune responses have reinvigorated the field after previous setbacks. However, challenges such as the virus's ability to evade immune responses and the need for different approaches for various age groups may impact market dynamics. Stringent regulatory requirements, given past vaccine-enhanced disease incidents, also influence development timelines and market entry. North America held the largest market share in 2023 and is expected to maintain its dominance in the forecast period, driven by robust research infrastructure and high healthcare expenditure.

Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market Key Develpments:

In August 2023, Pfizer received additional FDA approval for ABRYSVO, their RSV vaccine. This development:

• Expands the use of ABRYSVO to pregnant individuals
• Aims to prevent RSV in infants through maternal immunization
• Demonstrated 81.8% efficacy against severe medically attended lower respiratory tract illness in infants up to 6 months of age
• This represents a significant advancement in protecting newborns against RSV

In July 2023, Pfizer received FDA approval for ABRYSVO, their RSV vaccine for older adults. This development:

• Introduces a new RSV vaccine option for the older adult population
• Demonstrated 66.7% efficacy against RSV-associated lower respiratory tract illness with two or more symptoms
• Expands the arsenal of preventive measures against RSV in a vulnerable age group
• Marks a significant milestone in Pfizer's RSV vaccine program